|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 801 PENNSYLVANIA AVENUE, NW |
Address2 | Suite 700 |
| City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 9204-12
|
||||||||
|
6. House ID# 335890000
|
||||||||
| TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Courtney Piron |
Date | 4/20/2023 12:49:53 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Biosimilars
Drug Pricing
Fiscal year 2024 Appropriations
H.R.5376, Inflation Reduction Act Implementation
Importation
Value of Medicine
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office, Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leo |
Farber |
|
|
|
Joseph |
McGowan |
|
|
|
Taylor |
Booth |
|
|
|
Nora |
Connors |
|
|
|
Courtney |
Lee-Ashley |
|
|
|
Courtney |
Piron |
|
|
|
Seemin |
Pasha |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Antitrust Legislation
Bayh-Dole Act/March-In Rights
Biopharmaceutical Intellectual Property
Biosimilars
BPCIA
Compulsory licenses
Data Exclusivity
H.R. 2883/S. 148, Stop Stalling Access to Affordable Medications
H.R. 2884/S. 150, the Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act
H.R. 2891/S. 142, the Preserve Access to Affordable Generics and Biosimilars Act
H.R. 5376, Inflation Reduction Act Implementation
S. 79, Patent Coordination and Improvement Act of 2023
S. 113, Prescription Pricing for the People Act of 2023
Intellectual Property Issues in Response to coronavirus
Inter Parties Review at PTO
Patent Litigation Reform and Issues Related to Post Grant Proceedings at PTO
Patents
S.1435, Affordable Prescriptions for Patients Act of 2021
Section 101
WTO TRIPS Waiver
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leo |
Farber |
|
|
|
Joseph |
McGowan |
|
|
|
Taylor |
Booth |
|
|
|
Nora |
Connors |
|
|
|
Courtney |
Lee-Ashley |
|
|
|
Courtney |
Piron |
|
|
|
Seemin |
Pasha |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
340B Drug Discount Program
Accelerated Approval
Alternative Funding Programs
Biosimilar approval and reimbursement policy issues
BLOCKING Act
Cancer Moonshot
Cell, gene and radioligand therapies
Co-pay accumulator programs
COVID-19
Diversity in Clinical Trials
Drug cost and pricing policy issues
Drug shortages policy issues
FDA modernization policy issues
Foreign manufacturing policy issues
Genetically Targeted Technologies
H.R, 2534 - Preserving Rules Ordered for the Entities Covered Through (PROTECT) 340B Act
H.R. 5376 - Inflation Reduction Act Implementation
H.R. 5416, The Give Kids a Chance Act
The Medicaid VBPs for Patients (MVP) Act
H.R. 830, HELP Co-pays Act
H.R. 1613, The Drug Price Transparency in Medicaid Act
Intellectual property
Notice of Benefit Payment Parameters (NBPP)
Orphan Drugs
Outcomes based contracting/value based arrangements
Patient assistance program policy issues
PDUFA, BSUFA, GDUFA
Pharmaceutical quality
Pharmaceutical supply chain
Pharmacy benefit manager policy issues
Priority Review Voucher (PRV)
Regulatory efficiencies policy issues
S. 2837, 340B Accountability Act 2021
S. 476, The Maintaining Investments in New Innovations (MINI) Act
S.127, The Pharmacy Benefit Manager Transparency Act of 2023
Transparency policy issues
Utilization management policies
Vaccines
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), White House Office, Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leo |
Farber |
|
|
|
Joseph |
McGowan |
|
|
|
Taylor |
Booth |
|
|
|
Nora |
Connors |
|
|
|
Courtney |
Lee-Ashley |
|
|
|
Courtney |
Piron |
|
|
|
Seemin |
Pasha |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
ASP reporting policy issues
Center for Medicare and Medicaid Innovation (CMMI) policy issues
Drug Pricing
H.R. 5376, Inflation Reduction Act
Innovative Pharmaceuticals (including cell, gene and radioligand therapies), Biosimilars and Generics
Inflation Reduction Act Impact on Innovative Pharmaceuticals and implementation
Medicaid
Medicare Part A, B and D
Medicare Part D Negotiations
Medicare Part D Re-design and out of pocket cap
National coverage determination policies
Outcomes based Contracting/value based arrangements
Patient Cost-Sharing and Smoothing
Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals
Transparency policy issues
Advanced Safe Testing at Residence Telehealth Act of 2023
S. 476, The Maintaining Investments in New Innovations (MINI) Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), White House Office, Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leo |
Farber |
|
|
|
Joseph |
McGowan |
|
|
|
Taylor |
Booth |
|
|
|
Nora |
Connors |
|
|
|
Courtney |
Lee-Ashley |
|
|
|
Courtney |
Piron |
|
|
|
Seemin |
Pasha |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Pharmaceutical supply chain incentives
R&D Amortization
U.S. Corporate Tax
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leo |
Farber |
|
|
|
Joseph |
McGowan |
|
|
|
Taylor |
Booth |
|
|
|
Nora |
Connors |
|
|
|
Courtney |
Piron |
|
|
|
Seemin |
Pasha |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Access to Medicines Issues
Biopharmaceutical Innovation Policies
Free Trade Agreements - Intellectual Property and Transparency Provisions
Global Health Issues
India, China and Canada IP and Market Access Issues
Intellectual property
International Market Access and Intellectual Property Issues
Pharmaceutical Supply Chain
Pricing and reimbursement policy issues
Supply chain and China Task Force policy issues
Trade Policy
US Swiss Trade Relations
US Switzerland Mutual Recognition Agreement on GMP
WTO IP Waiver
17. House(s) of Congress and Federal agencies Check if None
U.S. Trade Representative (USTR), U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Commerce - Dept of (DOC), State - Dept of (DOS), U.S. Agency for International Development (USAID), Health & Human Services - Dept of (HHS), White House Office, Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leo |
Farber |
|
|
|
Joseph |
McGowan |
|
|
|
Taylor |
Booth |
|
|
|
Nora |
Connors |
|
|
|
Courtney |
Lee-Ashley |
|
|
|
Courtney |
Piron |
|
|
|
Seemin |
Pasha |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
Health care collaboration opportunities
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leo |
Farber |
|
|
|
Courtney |
Piron |
|
|
|
Joseph |
McGowan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LBR
16. Specific lobbying issues
Non-competes policies
Federal Trade Commission's Non-Compete Clause Proposed Rule
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leo |
Farber |
|
|
|
Joseph |
McGowan |
|
|
|
Courtney |
Piron |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MAN
16. Specific lobbying issues
H.R, 555 Securing America's Vaccines for Emergencies Act of 2023
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leo |
Farber |
|
|
|
Joseph |
McGowan |
|
|
|
Taylor |
Booth |
|
|
|
Nora |
Connors |
|
|
|
Courtney |
Piron |
|
|
|
Courtney |
Lee-Ashley |
|
|
|
Seemin |
Pasha |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |